Updated:
Element Materials Technology
Element Materials Technology is a global TIC platform led by CEO Jo Wetz, taken private by Bridgepoint and Temasek in 2023 at a $6B+ valuation.
Element Materials Technology
Element Materials Technology operates as one of the largest pure-play TIC platforms globally, serving asset-intensive industries where component failure is catastrophic. The firm's laboratories test materials, certify components, and validate processes for sectors that include aerospace, transportation, energy, fire safety, and connected technologies. Its customer base spans regulators, manufacturers, and infrastructure operators — demand is non-discretionary and tied to regulatory cycles rather than GDP. The company was acquired by Bridgepoint and Temasek in a deal that closed in early 2023, delisting Element from the London Stock Exchange. During its public-market tenure, Element executed over 30 bolt-on acquisitions that expanded its lab network across North America, Europe, and Asia. The strategy under private ownership continues this roll-up logic: acquire specialized laboratories with deep domain expertise, integrate them into Element's global quality-management system, and cross-sell testing services to multinational clients operating on multiple continents. Element is led by CEO Jo Wetz, who previously served as the firm's CFO. In early 2024, Element acquired Nanosyn, a US-based analytical testing business focused on the pharmaceutical and life sciences end-market (per the firm, January 2024). This transaction signaled a push beyond industrial TIC into adjacent regulated healthcare services, a counter-cyclical revenue stream. The company maintains a network of over 200 laboratories worldwide and employs thousands of scientists, engineers, and technicians. Structurally, Element is not a typical family office but a sponsor-backed platform built through acquisition. Its position inside Bridgepoint's portfolio makes it a holding with a defined exit window, not a permanent capital vehicle. For allocators, the firm represents a bet on the TIC superstructure — the outsourced compliance spine of global heavy industry — rather than on any single family wealth origin.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, United Kingdom
Principals
Jo Wetz
CEO
Sector focus
Frequently asked questions
Who owns Element Materials Technology, and what is the investment structure?
Bridgepoint and Temasek acquired Element in a take-private transaction that closed in early 2023. The deal valued the company at approximately $6.4 billion including debt, making it one of the largest European TIC buyouts. Element is held as a private portfolio company within Bridgepoint's flagship fund structure, with Temasek as a co-investor.
How does Element source its acquisition targets?
Element runs a proprietary M&A pipeline built on decades of industry relationships within the highly fragmented TIC sector. The firm identifies founder-owned or small-group laboratories with accredited testing capabilities and narrow domain expertise, then integrates them into Element's centralized quality-management and commercial infrastructure. This bolt-on strategy is the primary driver of both geographic expansion and service-line density.
What end-markets does Element's testing serve?
Element's laboratories test across aerospace, defense, energy, fire safety, connected technologies, and life sciences. In aerospace, this includes destructive and non-destructive testing of turbine blades, landing gear, and composite airframe components. In energy, the firm certifies materials for upstream oil and gas infrastructure as well as renewable-generation equipment. The life sciences vertical, expanded via the Nanosyn acquisition, focuses on pharmaceutical analytical testing.
Is Element exposed to any single regulatory regime?
No. Element's accreditations span major regulatory frameworks including FAA materials testing, NADCAP aerospace special-process certification, and FDA pharmaceutical analytical testing protocols. This diversification across regulators and geographies means no single government's policy shift materially threatens the revenue base. It also creates a barrier to entry for smaller laboratories that cannot afford the accreditation burden.
What is the expected exit path for Bridgepoint's investment?
Bridgepoint's standard fund lifecycle suggests a holding period of four to six years, positioning a potential exit around 2027 to 2029. Likely exit routes include a London or New York relisting, given Element's prior public-market history and the TIC sector's established valuation framework, or a secondary sale to infrastructure or long-duration private equity funds that prize TIC's contracted, recurring revenue profile.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: